Holen Sie sich die Stockscreener-App
12.93
0.96%
-0.2613
Schlusskurs vom Vortag:
$13.19
Offen:
$13.3
24-Stunden-Volumen:
461
Relative Volume:
1.72
Marktkapitalisierung:
$3.02M
Einnahmen:
$2.76M
Nettoeinkommen (Verlust:
$-112.96M
KGV:
-0.3682
EPS:
-35.1
Netto-Cashflow:
$-96.46M
1W Leistung:
+9.97%
1M Leistung:
-22.38%
6M Leistung:
-22.38%
1J Leistung:
-22.38%
1-Tages-Spanne:
$13.30
$13.30
1-Wochen-Bereich:
$12.17
$13.32
52-Wochen-Spanne:
$11.21
$14.30
Homology Medicines Inc Stock (FIXX) Company Profile
Firmenname
Homology Medicines Inc
Sektor
Branche
Telefon
781 301 7277
Adresse
One Patriots Park, Bedford
Compare FIXX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FIXX
Homology Medicines Inc
|
13.30 | 3.02M | 2.76M | -112.96M | -96.46M | -35.10 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Homology Medicines Inc Stock (FIXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | Raymond James | Strong Buy |
| 2024-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-17 | Eingeleitet | Guggenheim | Buy |
| 2024-05-21 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Piper Sandler | Overweight |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | Bestätigt | BTIG Research | Neutral |
| 2022-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-02-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2020-12-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-24 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-11-01 | Eingeleitet | Oppenheimer | Perform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-07 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-09-07 | Eingeleitet | B. Riley FBR | Neutral |
Alle ansehen
Homology Medicines Inc Aktie (FIXX) Neueste Nachrichten
Q32 Bio (FIXX) CSO logs automatic sale of 2,798 shares - Stock Titan
Q32 Bio (FIXX) CEO’s automatic tax sale leaves 343,259 shares - Stock Titan
Mucopolysaccharidosis Treatment Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
Leverage Shares 2X Long FIX Daily ETF ETF Price, Holdings, & News (BATS:FIXX) $FIXX - MarketBeat
Antineutrophil Cytoplasmic Antibody (ANCA) Associated - openPR.com
Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Mucolipidosis II Market - openPR.com
Emerging Sub-Segments Transforming the Lysosomal Enzyme Market Landscape - openPR.com
Form S-3 Q32 Bio Inc For: 17 July By Investing.com - Investing.com Canada
Q32 Bio (Nasdaq: QTTB) files to register 6.9M shares for resale - Stock Titan
Vitiligo Therapeutics Market Projected to Reach USD 2.28 Billion by 2032 - Yahoo Finance
Form 424B5 Q32 Bio Inc For: 15 July By Investing.com - Investing.com Canada
Form 424B5 Q32 Bio Inc For: 13 July By Investing.com - Investing.com Canada
Nucleic Acid Based Gene Therapy Market Report Evaluates Growth Drivers, Challenges And Market Dynamics - openPR.com
Q32 Bio (NASDAQ: QTTB) files $300M shelf; May 26 $55M placement noted - Stock Titan
Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary - Weekly Voice
Phenylketonuria Market Size, Share, Growth, Analysis, Report, 2034 - Straits Research
QTTBQ32 Bio Inc Stock Price and Quote - Finviz
This Q32 Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Sahm
Obesity Treatment Development: Challenges and Future Focus - Technology Networks
Mucolipidosis II Market Analysis: Major Segments, Strategic Developments, and Leading Companies - openPR.com
ATLAS VENTURE ASSOCIATES X L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga
Leading Companies Fueling Innovation and Growth in the Mucopolysaccharidosis Treatment Market - openPR.com
DEERFIELD PARTNERS L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Krabbe Disease Treatment Market Overview, Emerging Trends, and Key Player Analysis - openPR.com
Analysis of Key Market Segments Influencing the CRISPR Gene Editing Market - openPR.com
Deerfield Mgmt HIF L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Growth Patterns, Segment Analysis, and Competitive Approaches - openPR.com
Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026 - EIN News
Analysis of Market Segments and Major Growth Areas in the Nucleic Acid Based Gene Therapy Market - openPR.com
Biotech Expansion Accelerating Viral Vector Manufacturing Market Insights 2026–2035 - Weekly Voice
Q32 Bio Hits New HighRegrowth Signals? - RTTNews
Q32 Bio (QTTB) One Off Driven Q4 Profit Challenges Earnings Decline Narrative - Sahm
Q32 Bio Inc. 2025 Annual Report: Business Overview, Pipeline, Risks, and Intellectual Property Strategies - Minichart
Brain cancer drug developer hires CFO, CTO and CBO in strategic reset - Stock Titan
$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More - Yahoo Finance
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer - Business Wire
Editas Medicine nominates lead in vivo development candidate - BioWorld News
AAV for the Hereditary Retinal Diseases Clinical Trial - GlobeNewswire
OXB completes acquisition of remaining stake in US subsidiary - GlobeNewswire
Mucopolysaccharodisis Treatment Market Size & Share, 2033 - Market Data Forecast
Qatar’s $320bn wealth fund seeks to catch up on tech - businessreport.co.za
Stoke Therapeutics Announces CEO Transition - Business Wire
Q32 Bio Inc. (QTTB) reports earnings - qz.com
Versatope Adds New Board Members - citybiz
QTTB stock touches 52-week low at $2.59 amid market challenges - Investing.com
Homology Medicines (NASDAQ: FIXX)Share Price - intelligentinvestor.com.au
100 cell and gene therapy leaders to watch in 2025 - drugdiscoverytrends.com
Growth Trends in the CRISPR and Cas Gene Market: Industry Opportunities and Strategies to 2028 & 2033 - GlobeNewswire
Oxford BioMedica H1 Loss Narrows, Revenues Climb; Confirms FY24, Medium-term Outlook - RTTNews
Generation of a medicine food homology formula and its likely mechanism in treatment of microvascular angina - Frontiers
Could Q32 Bio’s ‘Skeleton Key’ Open the Door to New Treatments for an Array of Diseases? - University of Colorado Anschutz
Finanzdaten der Homology Medicines Inc-Aktie (FIXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Homology Medicines Inc-Aktie (FIXX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kalowski Lee | CFO and President |
Aug 25 '26 |
Sale |
16.56 |
3,972 |
65,776 |
138,471 |
| Violette Shelia M. | Chief Scientific Officer |
Aug 25 '26 |
Sale |
16.56 |
2,798 |
46,335 |
127,771 |
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):